AwesomeCapital
Search This Blog
Monday, November 25, 2019
Wells Fargo Starts Rapt Therapeutics (RAPT) at Outperform
Opportunities for CCR4 Inhibitor Program: analyst Yanan Zhu.
Target $33
https://www.streetinsider.com/Analyst+Comments/UPDATE%3A+Wells+Fargo+Starts+Rapt+Therapeutics+%28RAPT%29+at+Outperformon+Opportunities+for+CCR4+Inhibitor+Program/16173228.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.